LANTHEUS HOLDINGS, INC.

Drug pipeline (10)

Asset	Stage	Revenue	Trials	Status
DEFINITY	approved	$85.3MQ4 2025	4	approved
NEURACEQ	approved	$31.0MQ4 2025	2	approved
ABLAVAR	approved	—	0	—
BRAVNETSA	approved	—	0	—
DEFINITY RT	approved	—	4	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (42)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00891241	phase1	completed	2009-08-01	2009-11-01	Lantheus Medical Imaging	A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure
NCT01347710	phase3	completed	2011-06-01	2013-07-01	Lantheus Medical Imaging	A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
NCT00707538	phase1	completed	2008-06-01	2008-10-01	Lantheus Medical Imaging	A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress
NCT00707499	phase1	completed	2007-09-01	2008-05-01	Lantheus Medical Imaging	A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158
NCT00162058	phase2	completed	2004-03-01	2006-04-01	Lantheus Medical Imaging	A Phase II Study of DMP 115 to Assess Focal Liver Lesions

FDA applications (9)

Application

Approved

Type

Applicant

Products

NDA 220496

2026-08-13

NDA

CERVEAU TECHNOLOGIES INC A LANTHEUS CO

NDA 204677

2014-03-19

NDA

LANTHEUS BIOSCIENCES LTD

NDA 021711

2008-12-22

NDA

LANTHEUS MEDICAL IMAGING INC

NDA 021064

2001-07-31

NDA

LANTHEUS MEDICAL IMAGING INC

NDA 017806

1998-10-09

NDA

LANTHEUS MEDICAL IMAGING INC